Next-Generation Endocrine Therapies: Opportunities in ER+/HER2- Breast Cancer Care

Get the latest evidence on next-generation endocrine therapies for ER+/HER- breast cancer and optimal strategies for incorporating these agents into clinical practice with an on-demand webcast, downloadable slides, and an expert summary commentary from a live symposium.

Share

Program Content

Activities

ET in ER+/HER2- Breast Cancer
Navigating Endocrine Therapy and Resistance in ER+/HER2- Breast Cancer
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 01, 2023

SERDs and Novel ET in ER+/HER2- Breast Cancer
Oral SERDs and Novel Endocrine Therapies: Reshaping the Treatment Landscape for ER+/HER2- Breast Cancer
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 01, 2023

Activities

Endocrine Therapies for Breast Cancer
Next-Generation Endocrine Therapies: Opportunities in ER+/HER2- Breast Cancer Care
Video
Congratulations: You achieved a completion on 04/09/2022

Released: December 18, 2023

Expires: December 17, 2024

Activities

Next Gen ET Key Takeaways
Next-Generation Endocrine Therapies for ER+/HER2- Breast Cancer Care: Key Takeaways From Our Recent Symposium in San Antonio
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: December 20, 2023

Faculty

cover img faculity

Erika P. Hamilton, MD

Director, Breast Cancer Research Program
Sarah Cannon Research Institute
Tennessee Oncology
Nashville, Tennessee

cover img faculity

Kevin Kalinsky, MD, MS

Division Director, Medical Oncology
Professor, Department of Hematology and Medical Oncology
Winship Cancer Institute at Emory University
Atlanta, Georgia

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC

Supporters

Supported by an educational grant from AstraZeneca.

AstraZeneca